PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. 2025-03-21			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 12.38M 10.86M 10.26M 9.35M 17.5M 1.19B 17.63M 123M 47.55M 606M 46.48M 45.47M 1.95B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 17.56M 15.41M 14.55M 13.26M 24.82M 1.68B 25M 174M 67.44M 860M 65.92M 64.5M 2.76B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
24-08-21	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
24-06-24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
24-06-20	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
24-01-15	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
23-12-20	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-14	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
23-05-31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
23-05-31	PCL to Raise 36 Billion Won via Share Issuance	MT
23-03-22	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-12-28	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	87,700
5 years	5,900	340,000
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news: PCL, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	2024-03-27
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	2024-03-27

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	74	-
Mu-Yong So BRD	Director/Board Member	53	2024-03-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-90.38%	12.27M
IOVANCE BIOTHERAPEUTICS, INC.	+1.85%	+7.32%	+444.55%	+140.70%	4.89B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-0.47%	+2.87%	+124.14%	+479.33%	4.72B
VERACYTE, INC.	-6.41%	+14.16%	+38.42%	+102.18%	3.9B
CAREDX, INC.	+3.76%	+18.30%	+328.24%	+733.51%	3.17B
BGI GENOMICS CO., LTD.	+2.50%	+20.93%	-9.18%	-15.52%	2.58B
FREENOME, INC.	-4.59%	-8.24%	+48.11%	-	1.72B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.65%	+9.04%	+182.53%	-18.28%	1.14B
SEEGENE, INC.	-0.58%	+0.89%	+30.52%	+61.14%	1.13B
CURIOX BIOSYSTEMS CO., LTD	+5.08%	+3.98%	-17.88%	+84.39%	623M
Average	-0.16%	+6.00%	+116.95%	+164.12%	2.39B
Weighted average by Cap.	-0.34%	+8.55%	+177.59%	+258.76%

	2023	2024
Net sales	8.43B 6.21M 5.45M 5.15M 4.69M 8.78M 595M 8.84M 61.59M 23.85M 304M 23.32M 22.81M 977M	1.25B 918K 806K 761K 693K 1.3M 87.99M 1.31M 9.1M 3.53M 44.95M 3.45M 3.37M 144M
Net income	-20.32B -14.97M -13.13M -12.4M -11.3M -21.16M -1.43B -21.31M -148M -57.49M -733M -56.2M -54.98M -2.36B	-52.34B -38.56M -33.83M -31.95M -29.12M -54.51M -3.7B -54.9M -382M -148M -1.89B -145M -142M -6.07B
Net Debt	7.2B 5.31M 4.66M 4.4M 4.01M 7.5M 509M 7.56M 52.63M 20.39M 260M 19.93M 19.49M 835M	7.03B 5.18M 4.54M 4.29M 3.91M 7.32M 496M 7.37M 51.36M 19.89M 254M 19.44M 19.02M 815M